Enhanced Group

ENHA · NYSE

$1.10−$0.03 (−2.65%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $1.13

ENHA analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 6 analysts

Average $4.08 (+270.9% upside)

Low: $3.03
Now: $1.10
High: $5.25

Upgrades and downgrades

The latest rating actions, newest first

ENHA analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Sep 23, 2026	Initiates	Overweight	$4.00	43%
Canaccord Genuity	Aug 17, 2026	Maintains	Buy	$6.00 → $5.00	43%
Canaccord Genuity	Jun 16, 2026	Maintains	Buy	$6.00	43%
Canaccord Genuity	Jun 2, 2026	Initiates	Buy	$6.00	43%
LUCID CAPITAL MARKETS	May 11, 2026	Initiates	Buy	$15.00	24%

The case for and against

Updated Oct 23, 2026

Bull case

Enhanced Group is positioned favorably because it operates in the fast-growing performance-medicine segment of a $2T global wellness market, targeting a clear gap between lifespan and health span with a D2C model that can deepen personalization and lower acquisition costs over time. Its May 2026-launched Live Enhanced platform already offers 11 Rx products and two supplement stacks across 34 countries, while the Enhanced Games reached over 1B people globally and generated $32M in sponsorship contract value, validating an owned media engine that competitors lack. With management projecting revenue of $357M in 2028 from $57M in 2026 and the company funded through 2027 profitability after a $50M PIPE, the outlook is supported by strong growth, improving monetization, and two near-term catalysts.

Bear case

Enhanced Group is viewed negatively because it remains an early-stage, unproven business that has incurred losses since founding, started with $0 revenue earlier this year, and still carries going-concern risk despite only limited liquidity from a $20M working capital note and about $3M from SPAC redemptions. Its model is highly experimental and exposed to regulatory, reputational, and ethical risks tied to performance-enhancing substances, while the health and wellness market is crowded and better-capitalized competitors may outspend it on marketing and R&D. Although revenue could reach $271M by 2028 and the stock screens cheaply at 1.8x 2027E EV/Revenue, the 2Q26 cost burden, including the $52M Games investment and recurring 6-figure Breakers events, underscores heavy execution risk and dilution concerns.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.